drugset / Trial / NCT00253552
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
Treatment
Summary
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving colony-stimulating factors, such as G-CSF, to the donor helps the stem cells move from the bone marrow to the blood so they can be collected and stored. PURPOSE: This clinical trial is studying how well a G-CSF-treated donor bone marrow transplant works in treating patients with hematologic cancer or noncancer.
Timeline
- Start
- 2004-05
- Primary completion
- 2006-05
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | filgrastim | Protein / enzyme biologic | — | Subcutaneous |
| Background | Busulfan | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Cyclosporine | Peptide | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |